Abstract
We investigated 2-weekly intravenous irinotecan combined with oral capecitabine in patients with advanced gastroesophageal adenocarcinoma. In phase I, doses were escalated in chemotherapy naïve or pretreated patients to establish maximum tolerated doses (MTD). In phase II, patients were treated at MTD as first-line therapy with the primary end point of RECIST response. Dose levels in phase I were as follows: Level 1: irinotecan 150 mg m-2 on day 1; capecitabine 850 mg m-2 12-hourly on days 1-9. Level 2: as level 1 but capecitabine 1000 mg m-2. Level 3: as level 2 but irinotecan 180 mg m-2. Level 4: as level 3 but capecitabine 1250 mg m-2. In phase I, 21 patients were entered. Maximum tolerated dose was level 3. Dose-limiting toxicities were lethargy, diarrhoea, vomiting and mucositis. In phase II, 31 patients were entered at level 3. During the first six cycles, 13 of these patients underwent dose reduction and three patients stopped treatment for toxicity. A further six patients stopped for progressive disease. The commonest grade 3-4 toxicities were lethargy (20%), diarrhoea (17%), nausea (10%) and anorexia (10%). There were no treatment-related deaths. The response rate was 32% (95% CI 16-52%). Median overall survival was 10...Continue Reading
References
Jul 1, 1993·Cancer·A M MuradM Rausch
Jan 1, 1997·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·A WebbM Meehan
Dec 16, 1998·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·M MiwaH Ishitsuka
Apr 1, 2000·Lancet·J Y DouillardP Rougier
Nov 12, 2002·Surgical Oncology Clinics of North America·Linda Morris Brown, Susan S Devesa
Mar 29, 2003·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Werner ScheithauerDieter Depisch
Sep 5, 2003·Annals of Oncology : Official Journal of the European Society for Medical Oncology·M TewesU Vanhoefer
Sep 11, 2003·British Journal of Cancer·C-H KöhneH J Wilke
Dec 6, 2003·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Christophe TournigandAimery de Gramont
Jan 13, 2004·Cancer·Emilio BajettaUNKNOWN Italian Trials in Medical Oncology (I.T.M.O.) Group
Mar 18, 2004·British Journal of Cancer·E Van CutsemR L Schilsky
Aug 21, 2004·Annals of Oncology : Official Journal of the European Society for Medical Oncology·Y S HongJ Y Cho
Oct 30, 2004·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Olivier BouchéUNKNOWN Fédération Francophone de Cancérologie Digestive Group
Nov 3, 2004·Annals of Oncology : Official Journal of the European Society for Medical Oncology·S S WöhrerM Hejna
Nov 20, 2004·Annals of Oncology : Official Journal of the European Society for Medical Oncology·C PozzoR Bugat
Jan 26, 2005·Annals of Oncology : Official Journal of the European Society for Medical Oncology·M M BornerUNKNOWN Swiss Group for Clinical Cancer Research (SAKK), Berne, Switzerland
Mar 10, 2005·British Journal of Cancer·J P DelordR Bugat
Jun 2, 2005·British Journal of Cancer·K SumpterJ Oates
Jun 9, 2005·Annals of Oncology : Official Journal of the European Society for Medical Oncology·D W ReaC J A Punt
Jun 9, 2005·British Journal of Cancer·S LorenzenF Lordick
Jul 1, 2005·The New England Journal of Medicine·Chris TwelvesWerner Scheithauer
Citations
Jan 15, 2011·Langenbeck's Archives of Surgery·Katja OttMarkus Büchler
Oct 25, 2007·Expert Opinion on Pharmacotherapy·Alicia OkinesDavid Cunningham
Dec 24, 2008·Cancer Chemotherapy and Pharmacology·Alexandra LearyJ Oates
Jun 13, 2009·European Journal of Clinical Pharmacology·Michele D MignognaStefania Leuci
May 3, 2007·British Journal of Cancer·S C OhY H Kim
Apr 1, 2008·Gastric Cancer : Official Journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association·Katja OttJörg Rüdiger Siewert
Apr 17, 2008·Cancer Chemotherapy and Pharmacology·Smitha S KrishnamurthiScot C Remick
Aug 1, 2009·Medical Oncology·Fadi S FarhatMarwan G Ghosn
Aug 5, 2011·Drugs·Jaclyn YoongTrevor Leong
Apr 20, 2010·Expert Review of Anticancer Therapy·Fadi S FarhatMarwan G Ghosn